Table 1.
Baseline characteristics
| Nivolumab (n=221) | Placebo (n=111) | ||
|---|---|---|---|
| Median age, years (IQR) | 70 (65–74) | 71 (65–76) | |
| Sex | |||
| Male | 167 (76%) | 86 (78%) | |
| Female | 54 (24%) | 25 (23%) | |
| ECOG performance status score | |||
| 1 | 177 (80%) | 89 (80%) | |
| 0 | 44 (20%) | 22 (20%) | |
| Smoking status | |||
| Ex-smoker | 105 (48%) | 52 (47%) | |
| Non-smoker | 100 (45%) | 52 (47%) | |
| Current smoker | 15 (7%) | 6 (5%) | |
| Missing | 1 (<1%) | 1 (1%) | |
| Site of mesothelioma | |||
| Pleural | 211 (95%) | 105 (95%) | |
| Non-pleural | 10 (5%) | 6 (5%) | |
| PD-L1 status | |||
| <1% (negative) | 101 (46%) | 65 (59%) | |
| ≥1% (positive) | 60 (27%) | 26 (23%) | |
| Missing | 60 (27%) | 20 (18%) | |
| Histology | |||
| Epithelioid | 195 (88%) | 98 (88%) | |
| Non-epithelioid | 26 (12%) | 13 (12%) | |
| Asbestos exposure | |||
| Yes | 150 (68%) | 80 (72%) | |
| No | 65 (29%) | 30 (27%) | |
| Missing | 6 (3%) | 1 (1%) | |
| Line of treatment | |||
| Second line | 63 (29%) | 37 (33%) | |
| Third line | 124 (56%) | 66 (60%) | |
| Later than third line | 34 (15%) | 8 (7%) | |
| Time since mesothelioma diagnosis | |||
| Median time since diagnosis, months (IQR) | 17·8 (11·7–27·4) | 17·7 (10·9–25·7) | |
| Missing | 0 | 1 (1%) | |
Data are n (%), unless otherwise stated.